Clinical Trial Update: OXYMIND: Oxytocin-augmented Group Psychotherapy for Patients With Schizophrenia [NA]

View source ↗

Summary

Charité University in Berlin conducted a completed clinical trial evaluating oxytocin-augmented group psychotherapy for schizophrenia-spectrum disorders.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia Spectrum Disorders

Drugs mentioned

• Oxytocin (Oxytocin)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Schizophrenia Spectrum Disorders | NA | Status: COMPLETED